NextPlat (NXPL) Common Equity (2010 - 2026)
NextPlat's (NXPL) quarterly Common Equity came in at $16.5 million in Q2 2026, down 28.35% year-over-year from $23.0 million in Q2 2025, and down 0.54% quarter-over-quarter from $16.6 million in Q1 2026.
Analysis
NextPlat (NXPL) Common Equity (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Common Equity for 17 consecutive years, with $16.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Common Equity fell 28.35% year-over-year to $16.5 million in Q2 2026; TTM through Jun 2026 was $16.5 million, a 28.35% decrease from a year earlier, with the FY2025 full-year figure at $17.4 million, down 34.99% from the prior year.
- Common Equity was $16.5 million for Q2 2026 at NextPlat, down from $16.6 million in the prior quarter.
- Over five years, Common Equity peaked at $49.5 million in Q3 2023 and troughed at $16.5 million in Q2 2026.
- A 5-year average of $27.9 million and a median of $24.7 million in 2023 frame the typical range for Common Equity.
- Across the five-year window, Common Equity surged 4012.86% in 2022 and plunged 47.23% in 2025, its largest moves.
- Over 5 years, Common Equity stood at $25.8 million in 2022, then jumped by 86.56% to $48.1 million in 2023, then tumbled by 44.27% to $26.8 million in 2024, then sank by 34.99% to $17.4 million in 2025, then dropped by 5.38% to $16.5 million in 2026.
- The last three Common Equity figures came in at $16.5 million (Q2 2026), $16.6 million (Q1 2026), and $17.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 7.76 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 14.26 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 4.08 Bn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 33.02 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -1.77 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 597.21 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -191.48 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 768.16 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 42.44 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 16.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.49 Mn |
| Mar 31, 2026 | 16.57 Mn |
| Dec 31, 2025 | 17.42 Mn |
| Sep 30, 2025 | 21.55 Mn |
| Jun 30, 2025 | 23.01 Mn |
| Mar 31, 2025 | 24.85 Mn |
| Dec 31, 2024 | 26.80 Mn |
| Sep 30, 2024 | 29.79 Mn |
| Jun 30, 2024 | 36.97 Mn |
| Mar 31, 2024 | 47.09 Mn |
| Dec 31, 2023 | 48.09 Mn |
| Sep 30, 2023 | 49.54 Mn |
| Jun 30, 2023 | 28.42 Mn |
| Mar 31, 2023 | 24.63 Mn |
| Dec 31, 2022 | 25.78 Mn |
| Sep 30, 2022 | 18.19 Mn |
| Jun 30, 2022 | 22.70 Mn |
| Mar 31, 2022 | 23.71 Mn |
| Dec 31, 2021 | 17.53 Mn |
| Sep 30, 2021 | 18.65 Mn |